Dr. Dale Schenk to Discuss Parkinson's Disease at 2014 Rejuvenation Biotechnology Conference
DUBLIN, Ireland, Aug. 18, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion, today announced that Dale Schenk, PhD, the Company's President and Chief Executive Officer, will be presenting at the 2014 Rejuvenation Biotechnology Conference, a SENS Research Foundation Conference, on Friday, August 22, 2014.
Dr. Schenk will present during the Parkinson's Disease Session, which will feature the latest in Parkinson's disease research. The presentation will be available through the investor relations section of the Company's website at www.prothena.com.
Prothena Corporation plc is a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion. The Company focuses on therapeutic monoclonal antibodies directed specifically to disease-causing proteins and its antibody-based product candidates target a number of potential indications including AL and AA forms of amyloidosis (NEOD001), Parkinson's disease and related synucleinopathies (PRX002) and novel cell adhesion targets involved in inflammatory diseases and cancers (PRX003).
For more information, please visit the Company's website at www.prothena.com.
CONTACT: Investors: Tran Nguyen, CFO 650-837-8535, IR@prothena.com Media: Anita Kawatra 646-256-5116, email@example.com